The Duke Cancer Institute is a National Cancer Institute-designated Comprehensive Cancer Center, research facility, and hospital. The center is part of the Duke University School of Medicine and Duke University Health System located in Durham, North Carolina, United States.

During the past decade, Duke Comprehensive Cancer Center conducted 170 clinical trials. In the 10-year time frame, 170 clinical trials started and 98 clinical trials were completed, i.e. on average, 57.6% percent of trials that started reached the finish line to date. In the past 5 years, 81 clinical trials started and 43 clinical trials were completed. i.e. 53.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke Comprehensive Cancer Center" #1 sponsor was "Duke University" with 105 trials, followed by "Alliance for Clinical Trials in Oncology" with 97 trials sponsored, "Children's Oncology Group" with 56 trials sponsored, "Gynecologic Oncology Group" with 55 trials sponsored and "National Cancer Institute (NCI)" with 55 trials sponsored. Other sponsors include 253 different institutions and companies that sponsored additional 149 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke Comprehensive Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 348 trials as a collaborator, "Cancer and Leukemia Group B" with 20 trials as a collaborator, "SWOG Cancer Research Network" with 18 trials as a collaborator, "Eastern Cooperative Oncology Group" with 13 trials as a collaborator and "Genentech, Inc." with 10 trials as a collaborator. Other collaborators include 158 different institutions and companies that were collaborators in the rest 101 trials.

According to Clinical.Site data, the most researched conditions in "Duke Comprehensive Cancer Center" are "Breast Cancer" (56 trials), "Leukemia" (56 trials), "Brain and Central Nervous System Tumors" (52 trials), "Ovarian Cancer" (43 trials) and "Lung Cancer" (41 trials). Many other conditions were trialed in "Duke Comprehensive Cancer Center" in a lesser frequency.

Most popular intervention types in "Duke Comprehensive Cancer Center" are "Drug" (439 trials), "Biological" (136 trials), "Procedure" (102 trials), "Radiation" (91 trials) and "Other" (53 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (59 trials), "cyclophosphamide" (49 trials), "etoposide" (43 trials), "filgrastim" (43 trials) and "cisplatin" (41 trials). Other intervention names were less common.

The vast majority of trials in "Duke Comprehensive Cancer Center" are 456 trials for "All" genders, 105 trials for "Female" genders and 28 trials for "Male" genders.

Currently, there are NaN active trials in "Duke Comprehensive Cancer Center". undefined are not yet recruiting, 50 are recruiting, 46 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 386 completed trials in Duke Comprehensive Cancer Center, undefined suspended trials, and 85 terminated clinical trials to date.

Out of the total trials that were conducted in Duke Comprehensive Cancer Center, 161 "Phase 1" clinical trials were conducted, 258 "Phase 2" clinical trials and 135 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 49 trials that are defined as “Not Applicable".